Carine J.M. Doggen

Showing 1-8 of 8 articles

Two-year clinical outcome of all-comers treated with three highly dissimilar contemporary coronary drug-eluting stents in the randomised BIO-RESORT trial

Kok M, Zocca P, Buiten R, Danse PW, Schotborgh C, Scholte M, Hartmann M, Stoel M, van Houwelingen K, Linssen GCM, Doggen CJM, von Birgelen C

October 19, 2018 | 10.4244/EIJ-D-18-00336

Stents and scaffolds

Prediabetes and its impact on clinical outcome after coronary intervention in a broad patient population

Kok M, von Birgelen C, Sattar N, Zocca P, Löwik M, Danse PW, Schotborgh C, Scholte M, Hartmann M, Kant GD, Doelman CJA, Gin M, Stoel M, van Houwelingen K, Linssen GCM, IJzerman M, Doggen CJM, van der Heijden LC

October 12, 2018 | 10.4244/EIJ-D-17-01067

Clopidogrel or ticagrelor in acute coronary syndrome patients treated with newer-generation drug-eluting stents: CHANGE DAPT

Zocca P, van der Heijden LC, Kok M, Löwik M, Hartmann M, Stoel M, Louwerenburg H, de Man F, Linssen GCM, Knottnerus I, Doggen CJM, van Houwelingen K, von Birgelen C

November 20, 2017 | 10.4244/EIJ-D-17-00634

Coronary interventions

Three-year safety and efficacy of treating all-comers with newer-generation Resolute Integrity or PROMUS Element stents in the randomised DUTCH PEERS (TWENTE II) trial

van der Heijden LC, Kok M, Löwik M, Danse PW, Jessurun G, Hautvast R, van Houwelingen K, Stoel M, Hartmann M, Linssen GCM, Doggen CJM, von Birgelen C

April 20, 2017 | 10.4244/EIJ-D-16-00571

Coronary interventions

Value of the SYNTAX score for periprocedural myocardial infarction according to WHO and the third universal definition of myocardial infarction: insights from the TWENTE trial

Tandjung K, Lam MK, Sen H, de Man F, Louwerenburg H, Stoel M, van Houwelingen K, Linssen GCM, van der Palen J, Doggen CJM, von Birgelen C

July 20, 2016 | 10.4244/EIJY15M08_01

Coronary interventions

Patient preference regarding assessment of clinical follow-up after percutaneous coronary intervention: the PAPAYA study

Kok M, von Birgelen C, Lam MK, Löwik M, van Houwelingen K, Stoel M, Louwerenburg H, de Man F, Hartmann M, Doggen CJM, van Til J, IJzerman M

April 20, 2016 | 10.4244/EIJY15M10_06

Safety of second-generation drug-eluting stents three years after randomised use in the TWENTE trial

Löwik M, Lam MK, Sen H, Tandjung K, van Houwelingen K, de Man F, Stoel M, Louwerenburg H, Linssen GCM, Doggen CJM, von Birgelen C

March 20, 2015 | 10.4244/EIJY14M08_11

Assessment of the relation between initial culprit vessel patency in acute ST-elevation myocardial infarction and endothelial function

Kandhai-Ragunath J, Jorstad H, de Wagenaar B, de Man F, Stoel M, van Es J, Doelman CJA, Doggen CJM, Peters R, von Birgelen C

November 20, 2014 | 10.4244/EIJV10I7A137

Latest news

NEW ISSUE

State of the Art on ViV-TAVI; Transseptal Punctures; Endovascular Closure and TF-TAVI; Percutaneous PVL Closure: Long-Term Outcomes; and more

October 20, 2021

STATE OF THE ART

Valve-in-valve TAVI: a practical overview

Giuseppe Tarantini et al.

October 20, 2021

AHEAD OF PRINT

TAVI in younger (<70 years old) patients: the AMTRAC registry

Guy Witberg et al.

October 22, 2021

AHEAD OF PRINT

Impact of LVOT calcification in transfemoral TAVI patients

L. Waldschmidt et al.

Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial

Hironori Hara et al.

October 22, 2021

AHEAD OF PRINT

Serum caffeine causes adenosine-induced FFR overestimation

Hideaki Tanaka et al.